Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell, Provenzano et al. identify hyaluronan as a pivotal determinant of elevated interstitial fluid pressures (IFP) and vascular collapse in PDA. PEGPH20 treatment ablates stromal hyaluronan, normalizes IFP, and increases accessibility of tumor cells to anticancer drugs
Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related mortality, with cy...
Making up just over 3% of all new cancer cases in the United States, pancreatic cancer is not inhere...
Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs mig...
Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell...
SummaryPancreatic ductal adenocarcinomas (PDAs) are characterized by a robust fibroinflammatory resp...
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascul...
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascul...
Pancreatic ductal adenocarcinomas (PDAs) are notoriously aggressive and resistant to treatment. They...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases to affect humans, regardl...
Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in more than 250,...
AbstractProgression of cancer is often associated with interactions between cancer cells and extrace...
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes among cancers with a 5-years s...
The tumor microenvironment plays an important role in the initiation and progression of pancreatic a...
The tumor microenvironment plays an important role in the initiation and progression of pancreatic a...
BACKGROUND & AIMS: The stroma in pancreatic ductal adenocarcinoma (PDAC) contributes to its immu...
Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related mortality, with cy...
Making up just over 3% of all new cancer cases in the United States, pancreatic cancer is not inhere...
Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs mig...
Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell...
SummaryPancreatic ductal adenocarcinomas (PDAs) are characterized by a robust fibroinflammatory resp...
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascul...
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascul...
Pancreatic ductal adenocarcinomas (PDAs) are notoriously aggressive and resistant to treatment. They...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases to affect humans, regardl...
Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in more than 250,...
AbstractProgression of cancer is often associated with interactions between cancer cells and extrace...
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst outcomes among cancers with a 5-years s...
The tumor microenvironment plays an important role in the initiation and progression of pancreatic a...
The tumor microenvironment plays an important role in the initiation and progression of pancreatic a...
BACKGROUND & AIMS: The stroma in pancreatic ductal adenocarcinoma (PDAC) contributes to its immu...
Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related mortality, with cy...
Making up just over 3% of all new cancer cases in the United States, pancreatic cancer is not inhere...
Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs mig...